Sun Hsin-Yun, Singh Nina
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Clin Infect Dis. 2009 Mar 15;48(6):745-55. doi: 10.1086/597039.
Statins are increasingly being used to treat solid-organ transplant recipients for posttransplantation metabolic complications. In addition to improving dyslipidemia, statins also have manifold non-lipid-lowering effects. With regard to sepsis or infection, these agents modify the inflammatory cascades by pleiotropic actions at multiple levels and exhibit activities against opportunistic bacteria, fungi, and viruses that can cause serious infections in solid-organ transplant recipients. They also have synergistic interactions with antimicrobial agents. Statins with antimicrobial and immunomodulatory attributes might improve morbidity and mortality attributable to sepsis or infection in solid-organ transplant recipients.
他汀类药物越来越多地用于治疗实体器官移植受者的移植后代谢并发症。除改善血脂异常外,他汀类药物还具有多种非降脂作用。关于脓毒症或感染,这些药物通过在多个水平上的多效性作用来改变炎症级联反应,并对可在实体器官移植受者中引起严重感染的机会性细菌、真菌和病毒表现出活性。它们还与抗菌药物有协同相互作用。具有抗菌和免疫调节特性的他汀类药物可能会改善实体器官移植受者因脓毒症或感染所致的发病率和死亡率。